title: Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease.
abstract: BACKGROUND
  Low-density lipoprotein (LDL) that contains apolipoprotein (apo) C-III makes up only 10% to 20% of plasma LDL but has a markedly altered metabolism and proatherogenic effects on vascular cells.
  
  
  RESULTS
  We examined the association between plasma LDL with apoC-III and coronary heart disease in 320 women and 419 men initially free of cardiovascular disease who developed a fatal or nonfatal myocardial infarction during 10 to 14 years of follow-up and matched controls who remained free of coronary heart disease. Concentrations of LDL with apoC-III (measured as apoB in this fraction) were associated with risk of coronary heart disease in multivariable analysis that included the ratio of total cholesterol to high-density lipoprotein cholesterol, LDL cholesterol, apoB, triglycerides, or high-density lipoprotein cholesterol and other risk factors. In all models, the relative risks for the top versus bottom quintile of LDL with apoC-III were greater than those for LDL without apoC-III. When included in the same multivariable-adjusted model, the risk associated with LDL with apoC-III (relative risk for top versus bottom quintile, 2.38; 95% confidence interval, 1.54-3.68; P for trend <0.001) was significantly greater than that associated with LDL without apoC-III (relative risk for top versus bottom quintile, 1.25; 95% confidence interval, 0.76-2.05; P for trend=0.97; P for interaction <0.001). This divergence in association with coronary heart disease persisted even after adjustment for plasma triglycerides.
  
  
  CONCLUSIONS
  The risk of coronary heart disease contributed by LDL appeared to result to a large extent from LDL that contains apoC-III.
authors: Harvard School of Public Health, Department of Nutrition, 665 Huntington Avenue, Boston, MA 02115, USA.
authors: Carlos O
authors: CO
authors: Mendivil
authors: Eric B
authors: EB
authors: Rimm
authors: Jeremy
authors: J
authors: Furtado
authors: Stephanie E
authors: SE
authors: Chiuve
authors: Frank M
authors: FM
authors: Sacks
mesh_terms: D000328:Adult; D000368:Aged; D053305:Apolipoprotein C-III / Q000097:blood*; D001055:Apolipoproteins B / Q000097:blood; D003327:Coronary Disease / Q000097:blood* / Q000453:epidemiology*; D015914:Estrogen Replacement Therapy / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015228:Hypertriglyceridemia / Q000097:blood / Q000453:epidemiology; D008077:Lipoproteins, LDL / Q000097:blood*; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D053305:Apolipoprotein C-III; D001055:Apolipoproteins B; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D014280:Triglycerides